Paysign, the Henderson, Nevada-based payments company for plasma donors and pharmaceutical patient affordability programs, reported third-quarter 2026 revenue of $30.80 million on 9 November 2026, up 42.6%, with net income of $6.74 million and a 23.8% operating margin. Paysign does not name the plasma customer that is leaving, and Fintechbits could not identify it from the company’s SEC filing of the same results.

How Paysign Absorbs the Plasma Loss

Pharma revenue, the patient affordability side, more than doubled, up 109.8% to $16.62 million, as Paysign ended the quarter with 167 active patient affordability programs. Plasma revenue rose 7.5% to $13.83 million across 562 centers. After the quarter closed, a plasma customer said it will move payment processing for 113 centers to a provider where it has a banking relationship. Those centers generated $11.3 million in trailing 12-month revenue and $5.2 million in gross profit.

Paysign held its full-year 2026 revenue outlook at $114.0 million to $117.0 million and raised its profit guidance, and expects to exit 2026 with 445 to 450 plasma centers. Losing a client to a bank relationship is the structural risk for a non-bank processor, and CEO Mark Newcomer’s own explanation of the loss names it directly.

The numbers on the loss are specific. Paysign estimates a fourth-quarter impact of $1.5 million in revenue and $700 thousand in gross profit, and says it remains the processor for a number of the same customer’s other centers. Patient affordability is the bigger story: revenue per program rose about 32% to $99,524 a quarter, and processed claims rose about 55%. Paysign also says it is developing a software platform for plasma centers that needs regulatory clearance. Unrestricted cash rose to $34.54 million with no bank debt, which gives it room to absorb the plasma hit while that software work continues into 2027. Healthcare payments is drawing other fintechs, including Panacea’s PlexPay and Accertify’s HIPAA-ready fraud tools.